Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Depomed Inc (NASDAQ:DEPO)

26.93
Delayed Data
As of Aug 31
 -1.45 / -5.11%
Today’s Change
13.47
Today|||52-Week Range
33.74
+67.16%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.7B

Company Description

Depomed, Inc. manufactures and distributes pharmaceutical products. It is a specialty pharmaceutical company focused on the development and commercialization of products to treat pain and other central nervous system conditions. Its core products include Gralise (gabapentin), a once-daily product for the management of postherpetic neuralgia; Zipsor (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain; and Lazanda (fentanyl) nasal spray, a product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The company has developed and licensed a drug-delivery technology, Acuform. Depomed was founded by John W. Shell on August 7, 1995 and is headquartered in Newark, CA.

Contact Information

Depomed, Inc.
7999 Gateway Boulevard
Newark California 94560
P:(510) 744-8000
Investor Relations:
(650) 462-5900

Employees

Shareholders

Other institutional57.51%
Mutual fund holders55.25%
Individual stakeholders12.02%

Top Executives

James A. SchoeneckPresident, Chief Executive Officer & Director
August J. MorettiCFO, Senior VP & Head-Investor Relations
Gerd G. KochendoerferVice President-Technical Development & Quality
G. Srinivas RaoChief Medical Officer & Senior Vice President
Matthew M. GoslingSenior Vice President & General Counsel